Pharma & Biotech VC & Investment News
Biotechnology
French biotech Enterome has secured $19 million in private funding to accelerate development of its OncoMimics immunotherapy platform, as it continues to show encouraging early signs of clinical activity across both solid and blood cancers. 12 June 2025
Today's issue
Refine Search
Biotechnology
Switzerland-based HAYA Therapeutics, a biotech developing precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-related diseases, has raised $65 million in a Series A funding round. 9 May 2025
Biotechnology
Massachusetts-based PAQ Therapeutics, a biotech developing KRAS degraders for cancers lacking effective treatment options, has completed a $39 million Series B funding round. 8 May 2025
Biotechnology
NewLimit, a US biotech start-up dedicated to extending human lifespan through gene reprogramming, has raised $130 million in a Series B funding round. 7 May 2025
Pharmaceutical
US investment firm Deerfield Management has closed its latest fund with $600 million in commitments to support advances in drug development, healthcare delivery, and AI-powered technologies. 6 May 2025
Biotechnology
Some $45 million has been raised in a Series B financing round by Nuevocor, an IND-stage biotech developing therapies for genetic cardiomyopathy, a largely unaddressed condition, by targeting the underlying mechanical defects. 6 May 2025
Pharmaceutical
According to property advisor Knight Frank, venture capital (VC) funding into the UK life sciences sector reached £1.1 billion ($1.3 billion) in the first quarter of 2025, the strongest first quarter since 2021’s post-pandemic peak and around 36% increase versus fourth quarter 2024. 1 May 2025
Biotechnology
UK investment firm Aviva Capital Partners is supporting a major new life sciences expansion in south London, which aims to transform Sutton’s London Cancer Hub into one of the world’s leading centers for oncology research and treatment. 1 May 2025
Biotechnology
Shares of US clinical-stage biotech Biohaven rose 9.6% to $21.74 yesterday, after it announced an agreement with Oberland Capital Management for an investment of up to $600 million in the company, with the first tranche of $250 million of gross proceeds to be funded at closing on or before April 30, 2025. 29 April 2025
Pharmaceutical
The Novo Nordisk Foundation has opened its largest research funding initiative, the Challenge Programme, to applicants based outside Denmark for the first time, allowing researchers from the European Schengen area, Ireland and the UK to lead new collaborations. 29 April 2025
Biotechnology
Early-stage biotech Nova Anchora has secured a new investment to move its lead therapy for epidermolysis bullosa (EB) closer to clinical trials. 29 April 2025
Biotechnology
Chinese biotech LTZ Therapeutics has closed an oversubscribed series A+ financing round, raising $40 million to support its push into early-stage clinical development. 25 April 2025
Biotechnology
Swiss-American biotech Granite Bio has exited stealth mode with $100 million in funding and plans to advance two experimental antibodies aimed at a range of autoimmune conditions. 25 April 2025
Biotechnology
Dutch biotech Avidicure has launched with $50 million in seed financing to support development of a novel class of multifunctional antibody therapies for cancer. 24 April 2025
Biotechnology
US biotech Grove Biopharma has secured $30 million in a series A round to move its lead program targeting advanced prostate cancer into clinical trials and expand development of its synthetic biology platform, known as Bionic Biologics. 24 April 2025
Biotechnology
Xlife Sciences says that Veraxa Biotech is to list as a public company on the Nasdaq Global Market through a strategic merger with the special purpose acquisition company Voyager Acquisition Corp. 23 April 2025
Biotechnology
London, UK-based Alis Biosciences, an investment fund focused on returning capital to investors that is currently trapped in listed, development-stage biotech companies, has formally launched. 21 April 2025
Pharmaceutical
Pain is good. Or finding non-opioid ways to manage it is good, if Latigo Biotherapeutics’ $150 million March fundraise is anything to go by. 19 April 2025
Biotechnology
US biotech Myeloid Therapeutics has restructured its operations to concentrate on two cancer programs already in the clinic, a move that has resulted in staff reductions and an uncertain future for its early-stage research work. 16 April 2025
Biotechnology
Californian biotech Glycomine has raised $115 million in a Series C financing to advance its lead candidate, GLM101, into a Phase IIb trial. 16 April 2025
Biotechnology
US biotech Mural Oncology has halted all development of its lead candidate, nemvaleukin alfa, after the engineered cytokine failed to meet the primary endpoint in a Phase II melanoma trial — just weeks after a similar failure in ovarian cancer. The company now plans to explore strategic alternatives, including a potential sale. 16 April 2025
Pharmaceutical
Australian biotech PolyActiva has brought in seasoned pharma executive Jerry St Peter as chief executive, in a leadership shake-up timed with a fresh $25 million financing round and a push to commercialize its lead eye implant therapy in the USA. 19 June 2025
Pharmaceutical
US biotech Actio Biosciences has raised $66 million in a series B round topport its pipeline of genetically targeted therapies, with new funding led by Regeneron Ventures and repeat backing from Deerfield Management. 19 June 2025
Biotechnology
Chinese biotech start-up BioTroy Therapeutics has raised over 200 million renminbi ($28 million) in series A financing to advance clinical trials for its experimental immunotherapy targeting CD3L1, a novel immune checkpoint aimed at tough-to-treat tumors. The company also plans to expand its early-stage pipeline and grow its Shanghai-based R&D team. 18 June 2025
Biotechnology
EY today released its 35th annual Biotech Beyond Borders Report. This finds that the biopharma industry is currently at an inflection point – grappling with a unique environment of macroeconomic uncertainty and constrained access to capital, including high interest rates, inflation, shifting regulatory policies and tariff turmoil. 18 June 2025
Pharmaceutical
Draig Therapeutics, a clinical-stage company based in Cardiff, UK, and aiming to transform the treatment of neuropsychiatric diseases, today launched from stealth having raised a total of $140 million (£107 million) in the last nine months. 18 June 2025
Biotechnology
French biotech Enterome has secured $19 million in private funding to accelerate development of its OncoMimics immunotherapy platform, as it continues to show encouraging early signs of clinical activity across both solid and blood cancers. 12 June 2025
Biotechnology
Angelini Ventures has joined a syndicate of European life sciences investors to back Elkedonia, a French biotech developing a new class of neuroplastogens to treat depression and other neuropsychiatric conditions. 11 June 2025
Biotechnology
Boston, USA-based biotech Antares Therapeutics, launched yesterday with $177 million in Series A financing. 11 June 2025
Pharmaceutical
China-based biotech Innogen is making a strategic pivot toward international visibility following regulatory clearance of its first-in-class, ultra-long-acting GLP-1 receptor agonist for type 2 diabetes, alongside a move to go public on the Hong Kong Stock Exchange. 11 June 2025
Biotechnology
Spanish biotech SpliceBio has secured $135 million in series B financing to accelerate development of its experimental gene therapy, SB-007, for Stargardt disease and expand its broader pipeline of genetic medicines. 11 June 2025
Biotechnology
China-based Kelun-Biotech Biopharmaceutical announced the placement of 5,918,000 H shares under its general mandate, representing approximately 2.54% of the enlarged share capital of the company post the placement. The shares were placed at HK$331.8 per share, raising net proceeds of around US$250 million. 6 June 2025
Pharmaceutical
US biotech Trevi Therapeutics has raised around $115 million in a public stock offering, giving it fresh momentum to continue developing its investigational therapy Haduvio (nalbuphine) for chronic cough. 6 June 2025
Biotechnology
Genetic testing company 23andMe is preparing for a renewed auction of its assets after a federal judge agreed to reopen the sale process, following an eleventh hour bid from company co-founder Anne Wojcicki. 6 June 2025
Biotechnology
San Jose, USA-based biotech Allay Therapeutics today announced the completion of a $57.5 million Series D financing round with leading global investors. 5 June 2025
Pharmaceutical
Sweden’s Karolinska Development today revealed that its portfolio company OssDsign has carried out a directed share issue through an accelerated book-building procedure that brought the company approximately 158 million kronor ($16.5 million). 4 June 2025
Pharmaceutical
Philadelphia-based biotech Vivodyne has raised $40 million in series A funding to advance its fully robotic, AI-powered platform that tests drug candidates on lab-grown human tissues. 30 May 2025
Biotechnology
Vima Therapeutics, a Cambridge, USA-based clinical-stage biotechnology company focused on oral therapies for movement disorders, has launched with a $60 million Series A financing. 30 May 2025
Biotechnology
US biotech Moderna has reported encouraging early-stage results from a trial of its experimental vaccine for avian influenza, just as a significant federal funding agreement was unexpectedly withdrawn. 29 May 2025
Pharmaceutical
US biotech Syndeio Biosciences has launched with over $90 million in funding and a pipeline of synapse-targeting neurotherapies aimed at treating major depressive disorder, Alzheimer’s disease, and other central nervous system (CNS) conditions. 27 May 2025
Pharmaceutical
Privately-held German radiopharmaceutical company Isotope Technologies Munich (ITM) has announced a debt financing agreement for up to $262.5 million from funds managed by Blue Owl Capital. 27 May 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze